All In Biotech

Free tool

FAERS Monitor: Ziana

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050802 or its brand name (Ziana, Clindamycin Phosphate, Tretinoin). Reports on generic versions are filed under their own applications.

Reports

154

Serious

59

38% of reports

Hospitalization

25

Death reported

3

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective17
  • acne11
  • headache8
  • nausea8
  • pain7
  • diarrhoea6
  • dizziness6
  • dry skin6
  • erythema6
  • application site erythema5
  • application site pain5
  • flushing5
  • injury5
  • product use issue5
  • accidental exposure to product4

Reports by year received

View as table
YearReports
20082
20093
20103
20113
20127
20137
201423
201520
201640
20176
20189
20197
20205
20215
20226
20233
20241
20251
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,005 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
application site painSignal531.013.1117
application site erythemaSignal526.111.097
acneSignal1119.811.2179
injurySignal59.74.131
flushingSignal56.72.819
dry skinSignal66.12.821
accidental exposure to productSignal45.32.010
erythemaSignal64.01.811
product use issueSignal53.61.57
drug ineffective171.81.15
headache81.70.92
dizziness61.60.71
pain71.60.81
nausea81.40.71
diarrhoea61.30.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.